US2012196825A1PendingUtilityA1

Compositions and methods for modulating the immune system

43
Individually held — no corporate assignee on recordPriority: May 11, 2006Filed: Dec 12, 2011Published: Aug 2, 2012
Est. expiryMay 11, 2026(expired)· nominal 20-yr term from priority
Inventors:Patrick T. Prendergast
A61P 7/02A61K 31/497A61P 7/00A61P 7/06A61P 37/02A61P 37/06A61K 31/52
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair.

Claims

exact text as granted — not AI-modified
1 . A method for the treatment and/or prophylaxis of blood cell depletion, the method comprising:
 providing a therapeutically effective or prophylactically effective amount of oltipraz or a derivative, analogue, metabolite, prodrug or pharmaceutically acceptable salt thereof; and   administering the same to a subject in need thereof.   
     
     
         2 . The method as claimed in  claim 1  wherein the blood cell depletion results in at least one condition selected from the group consisting of neutropenia, thrombocytopenia, lymphocytopenia and anaemia. 
     
     
         3 . The method as claimed in  claim 1  wherein the oltipraz metabolite is metabolite 3. 
     
     
         4 . The method as claimed in  claim 1  wherein oltipraz or the derivative, analogue, metabolite, prodrug or pharmaceutically acceptable salt thereof is formulated with carboxymethyl cellulose to form a combined medicament. 
     
     
         5 . A pharmaceutical composition for use in the treatment of blood cell depletion, the composition comprising oltipraz or a derivative, analogue, metabolite, prodrug or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent and/or carrier. 
     
     
         6 . The pharmaceutical composition as claimed in  claim 5  wherein oltipraz is provided in the form of metabolite 3. 
     
     
         7 . The pharmaceutical composition as claimed in  claim 5  wherein the composition is formulated with carboxymethyl cellulose. 
     
     
         8 . A method for the treatment and/or prophylaxis of blood cell depletion, the method comprising:
 providing a therapeutically or prophylactically effective amount of at least one cytokinin compound; and   administering the same to a subject in need thereof.   
     
     
         9 . The method as claimed in  claim 8  further comprising the step of administering to the subject a therapeutically effective or prophylactically effective amount of oltipraz or a derivative, analogue, metabolite, prodrug or pharmaceutically acceptable salt thereof 
     
     
         10 . The method as claimed in  claim 8  wherein the cytokinin compound is N 6  isopentenyl adenosine or a derivative, analogue, metabolite, prodrug or pharmaceutically acceptable salt thereof. 
     
     
         11 . The method as claimed in  claim 10  wherein the N 6  isopentenyl adenosine or derivative, analogue, metabolite, prodrug or pharmaceutically acceptable salt thereof is formulated with carboxymethyl cellulose to form a combined medicament. 
     
     
         12 . A pharmaceutical composition for use in the treatment of blood cell depletion, the composition comprising N 6  isopentenyl adenosine or a derivative, analogue, metabolite, prodrug or pharmaceutically acceptable salt thereof, along with a pharmaceutically acceptable diluent and/or carrier. 
     
     
         13 . The pharmaceutical composition as claimed in  claim 12  wherein the composition is formulated with carboxymethyl cellulose. 
     
     
         14 . The pharmaceutical composition as claimed in  claim 12  further comprising oltipraz or a derivative, analogue, metabolite, prodrug or pharmaceutically acceptable salt thereof. 
     
     
         15 . A combined pharmaceutical composition for the prevention and/or treatment and/or amelioration of a blood cell deficiency disorder, such as neutropenia, thrombocytopenia or anaemia, the composition comprising a cytokinin compound and oltipraz or a derivative or functionally equivalent analogue thereof along with at least one pharmaceutically acceptable diluent. 
     
     
         16 . The composition as claimed in  claim 15  wherein the cytokinin compound is N 6  isopentenyl adenosine or an analogue or a pharmaceutically acceptable salt thereof. 
     
     
         17 . The composition as claimed in  claim 15  wherein the cytokinin compound is N 6  benzyl adenosine or an analogue or pharmaceutically acceptable salt thereof. 
     
     
         18 . The composition as claimed in  claim 15  wherein the analogue or derivative of oltipraz is selected from the group consisting of 3H-1,2-dithiole-3-thione, sulforaphane, narigin, 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione, ADT, ADO, 1,2-dithiole-3-thione, 1,2-dithiolane, 1,3-dithiole-2-thione and malotilate. 
     
     
         19 . A method of stimulating cellular DNA repair mechanisms in a subject in advance of or following exposure of the subject to radiation, the method comprising the steps of:
 providing a therapeutically or prophylactically effective amount of oltipraz or a derivative, analogue, metabolite or salt thereof, and   administering the composition to a subject in need thereof.   
     
     
         20 . The method as claimed in  claim 19  wherein the radiation exposure results from the subject undergoing travel in space. 
     
     
         21 . The method as claimed in  claim 19  wherein the analogue or derivative of oltipraz is selected from the group consisting of 3H-1,2-dithiole-3-thione, sulforaphane, narigin, 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione, ADT, ADO, 1,2-dithiole-3-thione, 1,2-dithiolane, 1,3-dithiole-2-thione and malotilate. 
     
     
         22 . The method as claimed in  claim 19  wherein the oltipraz metabolite is metabolite 3. 
     
     
         23 . A pharmaceutical composition for mediating DNA repair following radiation exposure comprising oltipraz or a derivative or analogue thereof along with a pharmaceutically acceptable carrier. 
     
     
         24 . The pharmaceutical composition as claimed in  claim 23  wherein the analogue or derivative of oltipraz is selected from the group consisting of 3H-1,2-dithiole-3-thione, sulforaphane, narigin, 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione, ADT, ADO, 1,2-dithiole-3-thione, 1,2-dithiolane, 1,3-dithiole-2-thione and malotilate. 
     
     
         25 . A method of treating and/or preventing radiation-induced immunosuppression, the method comprising the step of administering a therapeutically or prophylactically effective amount of N 6  isopentenyl adenosine to a subject in need thereof.

Join the waitlist — get patent alerts

Track US2012196825A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.